Dyskinesia

Differentiating Movement Disorders
B. Wayne Blount, MD, MPH
http://www.fpm.emory.edu/

Gene expression patterns in levodopa-induced dyskinesia
ftp://amusing.mit.edu/

Neural structures involved in the control of movement
http://www.cns.nyu.edu

Psychosis

http://www.pharmacology.arizona.edu

Kartagener Syndrome: a relentless triad
Betsy Ott
http://www.uwec.edu/

Subluxation Definitions and Component Models
Victor G. Strang, D.C.
http://w3.palmer.edu/

Neuropsychological disorders
http://www.tamiu.edu/

Fluctuations in Parkinson’s Disease “From Tim Conway to Ray Charles”
Stephen G. Reich, M.D.
http://www.umm.edu

Treatment of Parkinson’s Disease
Christopher Buchanan
http://faculty.smu.edu

Pharmacodynamics of Antipsychotics Anxiolytics and Sedative-Hypnotics

Yogesh Dwivedi, Ph.D.
http://www.uic.edu/

Recent Research and Clinical Implications - Parkinson Disease
http://depts.washington.edu/

Basal Ganglia
http://www.kumc.edu/


400 free full text published articles

1. No Association between PAWR Gene Polymorphisms and Tardive Dyskinesia in Schizophrenia Patients.
2. Clinical aspects and management of levodopa-induced dyskinesia.
3. Reversal of reserpine-induced orofacial dyskinesia and catalepsy by Nardostachys jatamansi.
4. Corticostriatal Plastic Changes in Experimental L-DOPA-Induced Dyskinesia.
5. Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats.
6. L-745,870 reduces L-3,4-dihydroxyphenlylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
7. Phenytoin-induced acute orofacial dyskinesia.
8. Two cases of primary ciliary dyskinesia with different responses to macrolide treatment.
9. Mutations in the novel protein PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions.
10. Somatosensory disinhibition in patients with paroxysmal kinesigenic dyskinesia.
11. Effect of chronic L-dopa or melatonin treatments after dopamine deafferentation in rats: dyskinesia, motor performance, and cytological analysis.
12. Mutations in radial spoke head genes and ultrastructural cilia defects in East-European cohort of primary ciliary dyskinesia patients.
13. Relevance of animal models to human tardive dyskinesia.
14. Ethical and Policy Considerations in the Application of Pharmacogenomic Testing for Tardive Dyskinesia: Case Study of the Dopamine D3 Receptor.
15. Primary Ciliary Dyskinesia in Children: A Review for Pediatricians, Allergists, and Pediatric Pulmonologists.
16. Dopamine dysregulation in a mouse model of paroxysmal nonkinesigenic dyskinesia.
17. Ultrastructural pathology of primary ciliary dyskinesia: report about 125 cases in Germany.
18. L-DOPA-Induced Dyskinesia and Abnormal Signaling in Striatal Medium Spiny Neurons: Focus on Dopamine D1 Receptor-Mediated Transmission.
19. Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia.
20. Imaging mass spectrometry reveals elevated nigral levels of dynorphin neuropeptides in L-DOPA-induced dyskinesia in rat model of Parkinson's disease.
21. Rapid response of disabling tardive dyskinesia to amantadine: a case report.
22. The locus coeruleus is directly implicated in L-DOPA-induced dyskinesia in parkinsonian rats: an electrophysiological and behavioural study.
23. Development and validation of a method of cilia motility analysis for the early diagnosis of primary ciliary dyskinesia.
24. Mast cell activation and clinical outcome in pediatric cholelithiasis and biliary dyskinesia.
25. Striatal Signaling in L-DOPA-Induced Dyskinesia: Common Mechanisms with Drug Abuse and Long Term Memory Involving D1 Dopamine Receptor Stimulation.
26. L-DOPA-induced dyskinesia is associated with regional increase of striatal dynorphin peptides as elucidated by imaging mass spectrometry.
27. Nitric Oxide Synthase Inhibitor Improves De Novo and Long-Term l-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats.
28. Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time.
29. Primary ciliary dyskinesia: evaluation using cilia beat frequency assessment via spectral analysis of digital microscopy images.
30. Reversible oral dyskinesia associated with quetiapine in an adolescent: a case-report.
31. No Evidence for an Association between Dopamine D2 Receptor Polymorphisms and Tardive Dyskinesia in Korean Schizophrenia Patients.
32. Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients.
33. Optic nerve projections in patients with primary ciliary dyskinesia.
34. Primary ciliary dyskinesia caused by homozygous mutation in DNAL1, encoding dynein light chain 1.
35. Mutations in PNKD causing paroxysmal dyskinesia alters protein cleavage and stability.
36. Tardive dyskinesia with clozapine dose reduction or withdrawal dyskinesia?
37. Analyzing clinical and electrophysiological characteristics of Paroxysmal Dyskinesia.
38. Delayed postnatal loss of P/Q-type calcium channels recapitulates the absence epilepsy, dyskinesia, and ataxia phenotypes of genomic Cacna1a mutations.
39. Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat.
40. The role of glyoxalases for sugar stress and aging, with relevance for dyskinesia, anxiety, dementia and Parkinson's disease.
41. [Tako-tsubo syndrome. Transient left ventricular dyskinesia. Presentation of our casuistics].
42. Lingual dyskinesia and tics: a novel presentation of copper-metabolism disorder.
43. A case of dramatic improvement of severe tardive dyskinesia after switch to aripiprazole.
44. Enhanced striatal cholinergic neuronal activity mediates L-DOPA-induced dyskinesia in parkinsonian mice.
45. Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia.
46. Population specificity of the DNAI1 gene mutation spectrum in primary ciliary dyskinesia (PCD).
47. Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia.
48. Levodopa-induced dyskinesia is associated with increased thyrotropin releasing hormone in the dorsal striatum of hemi-parkinsonian rats.
49. Otologic features in children with primary ciliary dyskinesia.
50. Infantile convulsions with paroxysmal dyskinesia (ICCA syndrome) and copy number variation at human chromosome 16p11.
51. Oxcarbazepine-induced tardive dyskinesia: A rare adverse reaction.
52. [GRK6, a new therapeutic approach to alleviate L-dopa-induced dyskinesia].
53. Basal Ganglia circuits underlying the pathophysiology of levodopa-induced dyskinesia.
54. Deletion of adenosine A₁ or A(₂A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease.
55. Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia.
56. Mitochondrial abnormalities in the putamen in Parkinson's disease dyskinesia.
57. Gradual onset of dyskinesia induced by mirtazapine.
58. Primary ciliary dyskinesia demonstrating atypical presentation of Kartagener's syndrome.
59. Maladaptive striatal plasticity in L-DOPA-induced dyskinesia.
60. Primary ciliary dyskinesia that responded to long-term, low-dose clarithromycin.
61. Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment.
62. An epilepsy/dyskinesia-associated mutation enhances BK channel activation by potentiating Ca2+ sensing.
63. Ciliated air-liquid cultures as an aid to diagnostic testing of primary ciliary dyskinesia.
64. Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in rats.
65. Dysphagia due to tardive dyskinesia.
66. mTORC1 signaling in Parkinson's disease and L-DOPA-induced dyskinesia: A sensitized matter.
67. Characteristics of chloride transport in nasal mucosa from patients with primary ciliary dyskinesia.
68. Factors influencing age at diagnosis of primary ciliary dyskinesia in European children.
69. Relapse of tardive dyskinesia due to reduction in clozapine dose.
70. New DNAH11 mutations in primary ciliary dyskinesia with normal axonemal ultrastructure.
71. Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease.
72. [Familial idiopathic paroxysmal kinesigenic dyskinesia: its natural history and a descriptive study in three Spanish families].
73. Primary ciliary dyskinesia in Amish communities.
74. Direct relief of levodopa-induced dyskinesia by stimulation in the area above the subthalamic nucleus in a patient with Parkinson's disease--case report.
75. [Value of nasal nitric oxide in the diagnosis of primary ciliary dyskinesia].
76. Familial Paroxysmal Kinesigenic Dyskinesia.
77. Familial Paroxysmal Nonkinesigenic Dyskinesia.
78. Primary Ciliary Dyskinesia.
79. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
80. Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study.
81. Objective measurement of dyskinesia in Parkinson's disease using a force plate.
82. Lung function in patients with primary ciliary dyskinesia: a cross-sectional and 3-decade longitudinal study.
83. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study.
84. Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia.
85. Founder mutation(s) in the RSPH9 gene leading to primary ciliary dyskinesia in two inbred Bedouin families.
86. Amoxapine-induced tardive dyskinesia.
87. No Evidence for Association between Tyrosine Hydroxylase Gene Val81Met Polymorphism and Susceptibility to Tardive Dyskinesia in Schizophrenia.
88. Sphincter of Oddi dysfunction: psychosocial distress correlates with manometric dyskinesia but not stenosis.
89. Primary ciliary dyskinesia: a consensus statement on diagnostic and treatment approaches in children.
90. Loss-of-function mutations in the human ortholog of Chlamydomonas reinhardtii ODA7 disrupt dynein arm assembly and cause primary ciliary dyskinesia.
91. Deletions and point mutations of LRRC50 cause primary ciliary dyskinesia due to dynein arm defects.
92. Diagnostic testing of patients suspected of primary ciliary dyskinesia.
93. Anatomic localization of dyskinesia in children with "profound" perinatal hypoxic-ischemic injury.
94. A 20-year experience of electron microscopy in the diagnosis of primary ciliary dyskinesia.
95. Treatment of Tardive Dyskinesia by tetrabenazine, clonazepam and vitamin E.
96. [Primary ciliary dyskinesia. Ciliopathies].
97. Health-related quality of life and unmet needs in patients with primary ciliary dyskinesia.
98. Conditional deletion of dnaic1 in a murine model of primary ciliary dyskinesia causes chronic rhinosinusitis.
99. Lung disease assessment in primary ciliary dyskinesia: a comparison between chest high-field magnetic resonance imaging and high-resolution computed tomography findings.
100. Disrupted ciliated epithelium shows slower ciliary beat frequency and increased dyskinesia.
101. Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease.
102. Primary ciliary dyskinesia.
103. Primary ciliary dyskinesia: Myths and realities.
104. Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia.
105. Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling.
106. Mortality and tardive dyskinesia: long-term study using the US National Death Index.
107. The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats.
108. Tardive dyskinesia following risperidone treatment in Tourette's syndrome.
109. Levodopa-induced dyskinesia and striatal signaling pathways.
110. {beta} subunit-specific modulations of BK channel function by a mutation associated with epilepsy and dyskinesia.
111. Mutations in radial spoke head protein genes RSPH9 and RSPH4A cause primary ciliary dyskinesia with central-microtubular-pair abnormalities.
112. Paroxysmal non-kinesigenic dyskinesia is caused by mutations of the MR-1 mitochondrial targeting sequence.
113. Motor worsening and tardive dyskinesia with aripiprazole in Lewy body dementia.
114. Ten year outcome of tardive dyskinesia during continuous treatment with first generation antipsychotics.
115. [Transient midventricular dyskinesia: tako-tsubo cardiomyopathy. The story continues].
116. Dyskinesia and parkinsonism in antipsychotic-naive patients with schizophrenia, first-degree relatives and healthy controls: a meta-analysis.
117. Familial dyskinesia and facial myokymia (FDFM): Follow-up of a large family and linkage to chromosome 3p21-3q21.
118. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
119. DNAI2 mutations cause primary ciliary dyskinesia with defects in the outer dynein arm.
120. Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease?
121. Successful twin birth following blastocyst culture of embryos derived from the immotile ejaculated spermatozoa from a patient with primary ciliary dyskinesia: a case report.
122. Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat.
123. Mutation of murine adenylate kinase 7 underlies a primary ciliary dyskinesia phenotype.
124. Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta.
125. Myocardial cell membrane stress ionic dyskinesia reversal by diltiazem.
126. Paroxysmal exercise-induced dyskinesia and epilepsy is due to mutations in SLC2A1, encoding the glucose transporter GLUT1.
127. Structural and functional lung disease in primary ciliary dyskinesia.
128. Botulinum toxin type A in the healing of ulcer following oro-mandibular dyskinesia in a patient in a vegetative state.
129. [Transient left midventricular dyskinesia: clinical features of a new variant].
130. Increase in the effectiveness of somatodendritic 5-HT-1A receptors in a rat model of tardive dyskinesia.
131. Placebo influences on dyskinesia in Parkinson's disease.
132. Aripiprazole (abilify) and tardive dyskinesia.
133. RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease.
134. [Clinical and ultrastructural features of ciliary dyskinesia].
135. Primary ciliary dyskinesia in mice lacking the novel ciliary protein Pcdp1.
136. Heterotaxy and complex structural heart defects in a mutant mouse model of primary ciliary dyskinesia.
137. Primary ciliary dyskinesia: considerations regarding six cases of Kartagener syndrome.
138. An interview with Jeffrey A. Lieberman: Tardive Dyskinesia. [interview by Sussman Norman].
139. [An 81-year-old female with paroxysmal dyskinesia of the tongue].
140. Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics.
141. Sporadic paroxysmal non-kinesigenic dyskinesia: a frequently-misdiagnosed movement disorder.
142. Improvement of chronic facial pain and facial dyskinesia with the help of botulinum toxin application.
143. Worsening of tardive dyskinesia due to clozapine therapy.
144. Diagnosing primary ciliary dyskinesia.
145. Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease.
146. Pulmonary radioaerosol mucociliary clearance in diagnosis of primary ciliary dyskinesia.
147. Primary ciliary dyskinesia: current state of the art.
148. Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia.
149. Theophylline, adenosine receptor antagonist prevents behavioral, biochemical and neurochemical changes associated with an animal model of tardive dyskinesia.
150. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment.
151. Chiropractic management of musculoskeletal pain secondary to tardive dyskinesia.
152. Heterotaxia, congenital heart disease, and primary ciliary dyskinesia.
153. Congenital heart disease and other heterotaxic defects in a large cohort of patients with primary ciliary dyskinesia.
154. Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease.
155. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.
156. High-resolution CT of patients with primary ciliary dyskinesia.
157. Diagnosis of common variable immunodeficiency in a patient with primary ciliary dyskinesia.
158. A common variant in combination with a nonsense mutation in a member of the thioredoxin family causes primary ciliary dyskinesia.
159. Nasal nitric oxide in atypical primary ciliary dyskinesia.
160. Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: role of oxidative stress pathway genes.
161. Carrier status for 3 most frequent CFTR mutations in Polish PCD/KS patients: lack of association with the primary ciliary dyskinesia phenotype.
162. Management of conventional antipsychotic-induced tardive dyskinesia.
163. [Dose reduction of conventional antipsychotics: does it reduce tardive dyskinesia?].
164. [Aborted sudden death secondary to recurrent transient apical dyskinesia].
165. Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice.
166. Normalization and expression changes in predefined sets of proteins using 2D gel electrophoresis: a proteomic study of L-DOPA induced dyskinesia in an animal model of Parkinson's disease using DIGE.
167. Living with primary ciliary dyskinesia: a prospective qualitative study of knowledge sharing, symptom concealment, embarrassment, mistrust, and stigma.
168. Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia.
169. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability.
170. [Lithoptysis in a patient with primary ciliary dyskinesia].
171. A case of choreoacanthocytosis with marked weight loss: impact of orolingual dyskinesia.
172. Mutations of DNAI1 in primary ciliary dyskinesia: evidence of founder effect in a common mutation.
173. Movement: the emerging genetics of primary ciliary dyskinesia.
174. Aripiprazole-related tardive dyskinesia.
175. Ear dyskinesia.
176. Nasal nitric oxide to diagnose primary ciliary dyskinesia in newborns.
177. DNAH5 mutations are a common cause of primary ciliary dyskinesia with outer dynein arm defects.
178. A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia.
179. Marked improvement in chronic tardive dyskinesia after changing to aripiprazole.
180. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients.
181. Tardive dyskinesia in schizophrenia is associated with prolactin-related sexual disturbances.
182. Mucus properties in children with primary ciliary dyskinesia: comparison with cystic fibrosis.
183. Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat.
184. Multidose risperidone treatment evaluated in a rodent model of tardive dyskinesia.
185. RPGR is mutated in patients with a complex X linked phenotype combining primary ciliary dyskinesia and retinitis pigmentosa.
186. Functional analysis of tardive dyskinesia: implications for assessment and treatment.
187. Long term results of unilateral posteroventral pallidotomy for antipsychotic drug induced tardive dyskinesia.
188. Identification of predicted human outer dynein arm genes: candidates for primary ciliary dyskinesia genes.
189. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease.
190. Mucociliary transport using 99mTc-albumin colloid: a reliable screening test for primary ciliary dyskinesia.
191. Identification and analysis of axonemal dynein light chain 1 in primary ciliary dyskinesia patients.
192. Resolution of Ziprasidone-Related Tardive Dyskinesia With a Switch to Aripiprazole.
193. Mislocalization of DNAH5 and DNAH9 in respiratory cells from patients with primary ciliary dyskinesia.
194. Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3,4-dihydroxyphenylalanine-induced dyskinesia.
195. Subcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson's disease and L-DOPA-induced dyskinesia.
196. Tardive dyskinesia in 2 patients treated with ziprasidone.
197. Molecular diagnosis of pseudohypoparathyroidism type Ib in a family with presumed paroxysmal dyskinesia.
198. Abnormal cortical and spinal inhibition in paroxysmal kinesigenic dyskinesia.
199. Handedness and situs inversus in primary ciliary dyskinesia.
200. Analogue functional analysis of movements associated with tardive dyskinesia.
201. Nasal nitric oxide is low early in life: case study of two infants with primary ciliary dyskinesia.
202. Orolingual dyskinesia in central pontine myelinolysis.
203. Living with primary ciliary dyskinesia (PCD).
204. The gene for paroxysmal non-kinesigenic dyskinesia encodes an enzyme in a stress response pathway.
205. Nasal nitric oxide measurements to screen children for primary ciliary dyskinesia.
206. Nasal nitric oxide: clue to a diagnosis of ciliary dyskinesia.
207. Risperidone and olanzapine induced tardive dyskinesia : a critical review of reported cases.
208. Clinical and familial correlates of tardive dyskinesia in India and Israel.
209. Primary ciliary dyskinesia: genes, candidate genes and chromosomal regions.
210. Risperidone improves severe tardive dyskinesia in people with schizophrenia.
211. Discharge rate of substantia nigra pars reticulata neurons is reduced in non-parkinsonian monkeys with apomorphine-induced orofacial dyskinesia.
212. Paroxysmal kinesigenic dyskinesia manifestation of hyperthyroidism.
213. A Case Report of Methylphenidate-Induced Dyskinesia.
214. Loci for primary ciliary dyskinesia map to chromosome 16p12.1-12.2 and 15q13.1-15.1 in Faroe Islands and Israeli Druze genetic isolates.
215. Central microtubular agenesis causing primary ciliary dyskinesia.
216. Apparent X-linked primary ciliary dyskinesia associated with retinitis pigmentosa and a hearing loss.
217. Cerebrotendinous xanthomatosis with oromandibular dyskinesia.
218. Clinical, molecular, and PET study of a case of aceruloplasminaemia presenting with focal cranial dyskinesia.
219. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease.
220. "Neck Dyskinesia With Olanzapine-a case report".
221. Primary ciliary dyskinesia: diagnostic and phenotypic features.
222. [Primary ciliary dyskinesia in children]
223. Primary ciliary dyskinesia as a cause of neonatal respiratory distress: implications for the neonatologist.
224. Primary ciliary dyskinesia (Siewert's/Kartagener's syndrome): respiratory symptoms and psycho-social impact.
225. Investigation of the possible role of a novel gene, DPCD, in primary ciliary dyskinesia.
226. Atypical antipsychotics and tardive dyskinesia.
227. Neuroleptic drug exposure and incidence of tardive dyskinesia: a records-based case-control study.
228. 3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.
229. Nitric oxide metabolites are not reduced in exhaled breath condensate of patients with primary ciliary dyskinesia.
230. Spontaneous dyskinesia in first-degree relatives of chronically ill, never-treated people with schizophrenia.
231. Smoking and tardive dyskinesia: lack of involvement of the CYP1A2 gene.
232. Reliability and clinical utility of a Portuguese version of the Abnormal Involuntary Movements Scale (AIMS) for tardive dyskinesia in Brazilian patients.
233. Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics.
234. Chemotaxis of blood neutrophils from patients with primary ciliary dyskinesia.
235. [Pyridoxine in the management of tardive dyskinesia].
236. Nasal nitric oxide measurements for the screening of primary ciliary dyskinesia.
237. Comparison of exhaled and nasal nitric oxide and exhaled carbon monoxide levels in bronchiectatic patients with and without primary ciliary dyskinesia.
238. Olanzepine-induced tardive dyskinesia.
239. Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6.
240. Primary ciliary dyskinesia.
241. Risperidone induced tardive dyskinesia - a case report.
242. Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia.
243. Spontaneous dyskinesia and parkinsonism in never-medicated, chronically ill patients with schizophrenia: 18-month follow-up.
244. Mutations in the DNAH11 (axonemal heavy chain dynein type 11) gene cause one form of situs inversus totalis and most likely primary ciliary dyskinesia.
245. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism.
246. Carvedilol attenuates neuroleptic-induced orofacial dyskinesia: possible antioxidant mechanisms.
247. Short and long term prognostic importance of regional dyskinesia versus akinesia in acute myocardial infarction.
248. Freeze fracture study of airway epithelium from patients with primary ciliary dyskinesia.
249. Loss of function of axonemal dynein Mdnah5 causes primary ciliary dyskinesia and hydrocephalus.
250. Mutations in DNAI1 (IC78) cause primary ciliary dyskinesia.
251. Identification of dynein heavy chain 7 as an inner arm component of human cilia that is synthesized but not assembled in a case of primary ciliary dyskinesia.
252. Amphetamine-induced dopamine release and post-synaptic specific binding in patients with mild tardive dyskinesia.
253. Neurodevelopmental origins of tardivelike dyskinesia in schizophrenia patients and their siblings.
254. Tardive dyskinesia--diagnostic issues, subsyndromes, and concurrent movement disorders: a study of state hospital inpatients referred to a movement disorder consultation service.
255. Germline mutations in an intermediate chain dynein cause primary ciliary dyskinesia.
256. Tetrabnazine for isolated shoulder tardive dyskinesia.
257. Increased ictal perfusion of the thalamus in paroxysmal kinesigenic dyskinesia.
258. Primary ciliary dyskinesia syndrome associated with abnormal ciliary orientation in infants.
259. [Primary ciliary dyskinesia. report of three cases].
260. Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia.
261. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia.
262. Axonemal dynein intermediate-chain gene (DNAI1) mutations result in situs inversus and primary ciliary dyskinesia (Kartagener syndrome).
263. Risperidone - induced tardive dyskinesia : case report and review of literature.
264. Homozygosity mapping of a gene locus for primary ciliary dyskinesia on chromosome 5p and identification of the heavy dynein chain DNAH5 as a candidate gene.
265. Paroxysmal non-kinesigenic dyskinesia: pathophysiological investigations.
266. Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia.
267. Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease.
268. Nigrostriatal lesions alter oral dyskinesia and c-Fos expression induced by the serotonin agonist 1-(m-chlorophenyl)piperazine in adult rats.
269. Effect of L-arginine infusion on airway NO in cystic fibrosis and primary ciliary dyskinesia syndrome.
270. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group.
271. Risperidone implicated in the onset of tardive dyskinesia in a young woman.
272. Primary ciliary dyskinesia associated with a novel microtubule defect in a child with Down's syndrome.
273. Primary ciliary dyskinesia: a genome-wide linkage analysis reveals extensive locus heterogeneity.
274. A locus for primary ciliary dyskinesia maps to chromosome 19q.
275. The effect of regular salbutamol on lung function and bronchial responsiveness in patients with primary ciliary dyskinesia.
276. Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E.
277. An ambulatory dyskinesia monitor.
278. Loss-of-function mutations in a human gene related to Chlamydomonas reinhardtii dynein IC78 result in primary ciliary dyskinesia.
279. Educational video: primary ciliary dyskinesia-How to treat it and live with it
280. Nasal and lower airway level of nitric oxide in children with primary ciliary dyskinesia.
281. A possible mechanism of primary ciliary dyskinesia: a case of a segmental defect in ciliary microtubules.
282. Effect of aerosolized uridine-5'-triphosphate on airway clearance with cough in patients with primary ciliary dyskinesia.
283. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia.
284. Thalamotomy for severe antipsychotic induced tardive dyskinesia and dystonia.
285. Exclusion of chromosome 7 for Kartagener syndrome but suggestion of linkage in families with other forms of primary ciliary dyskinesia.
286. Spontaneous dyskinesia in first episode schizophrenia.
287. Primary ciliary dyskinesia: diagnosis and standards of care.
288. Sudden appearance of invalidating dyskinesia-dystonia and off fluctuations after the introduction of levodopa in two dopaminomimetic drug naive patients with stage IV Parkinson's disease.
289. Airway response of children with primary ciliary dyskinesia to exercise and beta2-agonist challenge.
290. Neurobiological characterization of bipolar affective disorders : a focus on tardive dyskinesia and soft neurological signs in relation to serum dopamine Beta hydroxylase activity.
291. Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia.
292. Longitudinal study of lung function in a cohort of primary ciliary dyskinesia.
293. Biliary dyskinesia: role of the sphincter of Oddi, gallbladder and cholecystokinin.
294. Bilateral posteroventral pallidotomy for severe antipsychotic induced tardive dyskinesia and dystonia.
295. [Neuroleptic medication and the risk of tardive dyskinesia: a survey of psychiatrists and general practitioners in Quebec].
296. Tardive dyskinesia exacerbated after ingestion of phenylalanine by schizophrenic patients.
297. Gallbladder dyskinesia in children.
298. Treatment of tardive dyskinesia.
299. Vulnerability to tardive dyskinesia development in schizophrenia: an FDG-PET study of cerebral metabolism.
300. A gene for familial paroxysmal dyskinesia (FPD1) maps to chromosome 2q.
301. Is resection of bronchiectasis beneficial in patients with primary ciliary dyskinesia?
302. The moving ear syndrome: a focal dyskinesia.
303. Pesistent parkinsonism and tardive dyskinesia.
304. Successful treatment of intractable tardive dyskinesia with botulinum toxin.
305. Fertility in men with primary ciliary dyskinesia presenting with respiratory infection.
306. Unusual inheritance of primary ciliary dyskinesia (Kartagener's syndrome).
307. Respiratory dyskinesia. An underrecognized phenomenon.
308. Risk factors for tardive dyskinesia.
309. Is the social acceptability of psychiatric patients decreased by orofacial dyskinesia?
310. Respiratory dysrhythmias in patients with tardive dyskinesia.
311. Ciliary disorientation: a possible variant of primary ciliary dyskinesia.
312. Vitamin E in the treatment of tardive dyskinesia.
313. Tardive dyskinesia.
314. Tardive dyskinesia presenting as severe dysphagia.
315. Primary ciliary dyskinesia.
316. Intracavitary repair of ventricular aneurysm and regional dyskinesia.
317. Gender differences in tardive dyskinesia: a critical review of the literature.
318. Primary ciliary dyskinesia.
319. Neutrophil function in dogs with congenital ciliary dyskinesia.
320. Dickens, dystonia and dyskinesia.
321. Neuroleptics and tardive dyskinesia--a case of iatrogenesis.
322. Tardive dyskinesia.
323. Mucociliary clearance from central airways in patients with excessive sputum production with and without primary ciliary dyskinesia.
324. Tardive dyskinesia successfully treated with alprazolam.
325. Sulpiride in tardive dyskinesia.
326. Tardive dyskinesia: a potential new neurochemical animal model.
327. Low dose levodopa in tardive dyskinesia.
328. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.
329. Respiratory failure due to vocal cord dyskinesia in olivo-ponto-cerebellar atrophy.
330. Dyskinesia in the elderly presenting as respiratory disorder.
331. Striatal dopamine D2 receptors in tardive dyskinesia: PET study.
332. Orientation of respiratory tract cilia in patients with primary ciliary dyskinesia, bronchiectasis, and in normal subjects.
333. Mortality rate of schizophrenic patients with tardive dyskinesia during 10 years: a controlled study.
334. Topographic subtypes of tardive dyskinesia in schizophrenic patients aged less than 60 years: relationship to demographic, clinical, treatment, and neuropsychological variables.
335. Chronic pneumonia in a child with primary ciliary dyskinesia.
336. Tardive dyskinesia.
337. Tardive dyskinesia.
338. Tardive dyskinesia.
339. Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms.
340. Clinical and biochemical effects of gamma-vinyl Gaba in tardive dyskinesia.
341. The impact of neuroleptic medication on tardive dyskinesia: a meta-analysis of published studies.
342. Impaired sensorimotor integration in parkinsonism and dyskinesia: a role for corollary discharges?
343. Role of the basal ganglia and cerebral cortex in tardive dyskinesia: evidence from cerebrovascular accident.
344. Paradoxical response of sphincter of Oddi to intravenous injection of cholecystokinin or ceruletide. Manometric findings and results of treatment in biliary dyskinesia.
345. The irregularly irregular pattern of respiratory dyskinesia.
346. Episodic laryngeal dyskinesia. Clinical and psychiatric characterization.
347. Assessment of the therapeutic range of tiapride in patients with tardive dyskinesia.
348. Resolution of dyskinesia and the "on-off" phenomenon in thyrotoxic patients with Parkinson's disease after antithyroid treatment.
349. Abnormal eye-head coordination in Parkinson's disease patients after administration of levodopa: a possible substrate of levodopa-induced dyskinesia.
350. Tardive dyskinesia associated with metoclopramide.
351. A trial of sodium valproate in tardive-dyskinesia.
352. Minimization and overreaction to tardive dyskinesia.
353. Anosognosia in tardive dyskinesia: "tardive dysmentia" or "tardive dementia"?
354. A 10-year follow-up study of tardive dyskinesia--with special reference to the influence of neuroleptic administration on the long-term prognosis.
355. Nomifensine-induced dyskinesia.
356. Persistent akathisia associated with early dyskinesia.
357. Metoclopramide and tardive dyskinesia in the elderly.
358. Primary ciliary dyskinesia.
359. Levodopa-induced dyskinesia and thalamotomy.
360. A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia.
361. Hydrocephalus and primary ciliary dyskinesia.
362. A case of tardive dyskinesia caused by metoclopramide.
363. Persistent akathisia associated with early tardive dyskinesia.
364. Tardive dyskinesia associated with metoclopramide.
365. Tardive dyskinesia: clinical correlation with computed tomography in patients aged less than 60 years.
366. Ciliary dyskinesia with normal ultrastructure.
367. Sustained levodopa therapy in tardive dyskinesia.
368. State-dependent tardive dyskinesia in manic-depressive illness.
369. Metoclopramide in tardive dyskinesia.
370. Tardive dyskinesia in a nonpsychiatric patient due to short-term use of a neuroleptic/anticholinergic combination drug.
371. Drug-induced parkinsonism and tardive dyskinesia in nonpsychiatric patients.
372. Dyskinesia induced by mefanimic acid?
373. Cystic fibrosis ciliary dyskinesia substances and pulmonary disease. Effects of ciliary dyskinesia substances on neutrophil movement in vitro.
374. Tardive dyskinesia.
375. Use of propranolol in treating tardive dyskinesia.
376. Tardive dyskinesia.
377. Psychiatry-epitomes of progress: tardive dyskinesia.
378. Symptomatic treatment of tardive dyskinesia: a word of caution.
379. The use of propranolol in treating tardive dyskinesia.
380. Synthesis and secretion of cystic fibrosis ciliary dyskinesia substances by purified subpopulations of leukocytes.
381. Treatment of tardive dyskinesia with choline and tetrabenazine.
382. Clinical aspects of dyskinesia.
383. Oxiperomide in tardive dyskinesia.
384. Tardive dyskinesia.
385. Tardive dyskinesia treated with clonidine.
386. Neuroleptic plasma levels and tardive dyskinesia.
387. Neuroleptic plasma levels and tardive dyskinesia: a possible link?
388. Tardive dyskinesia: clinical, biological, and pharmacological perspectives.
389. Tardive dyskinesia.
390. The effect of metoclopramide and haloperidol on tardive dyskinesia [proceedings].
391. Six month evaluation of thiopropazate hydrochloride in tardive dyskinesia.
392. Methodological issues in tardive dyskinesia research.
393. In search of treatment for tardive dyskinesia: review of the literature.
394. Depot fluphenazine and tardive dyskinesia.
395. Sodium valproate in the treatment of levodopa-induced dyskinesia.
396. Phenobarbital dyskinesia.
397. Tardive dyskinesia associated with metoclopramide.
398. Tardive dyskinesia treated with manganese.
399. Tardive dyskinesia treated with deanol acetamidobenzoate.
400. Tardive dyskinesia and pimozide.